Field notes for APOE4 carriers
Just found out you carry APOE4? One copy roughly triples Alzheimer’s risk and two copies raise it further, but a large share of that risk is modifiable. We turn the research, podcasts, and expert guidance into clear steps for protecting your brain and heart, with the real numbers and the honest uncertainty left in.
Free, and built for carriers by people who actually read the studies.
Browse
Plain-language deep dives that translate the science into what it means for you, and what to do about it.
What the gene is and what it means for you.
Alzheimer’s risk and neurodegeneration.
Cholesterol, lipids, and cardiovascular risk.
Fats, carbs, and eating for the APOE4 brain.
Training that protects brain and body.
Recovery, glymphatics, and resilience.
New studies, trials, and what they mean.
Editor’s picks
Start with the essentials every carrier should understand.
Relative risk, absolute risk, and age of onset: how to read the scary statistics about APOE4 and Alzheimer’s, with real ranges and the hopeful part that gets buried.
APOE4 does not only affect the brain. It shapes how your body handles cholesterol, which makes cardiovascular health the most concrete, trackable, and treatable lever carriers have.
APOE4 is the most common genetic risk factor for late-onset Alzheimer’s. What the gene does, what carrying one or two copies means, and the crucial things it does not mean.
Stay current
Short, dated summaries of new studies and developments, so you stay current without drowning in PubMed.
Browse the full digest →The arrival of anti-amyloid antibodies makes your APOE status relevant to treatment safety, not just to risk. The short version.
Source: Alzheimer’s Association: Lecanemab (Leqembi)
Often symptomless, and one of the best-established modifiable dementia risk factors. Don’t let it slip under the radar.
Source: World Health Organization: Dementia
What this digest is, who it’s for, and how to get the most out of it.
Why the modifiable-risk-factor framing matters so much for APOE4 carriers, and what the 2024 Lancet Commission found about reducing it.
Source: Livingston et al. (2024), The Lancet Commission: dementia prevention, intervention, and care
The phase 3 EVOKE trials of oral semaglutide in early Alzheimer’s missed their primary endpoint. Treating disease is not the same question as preventing it.
Source: Alzheimer Europe / Novo Nordisk, 2025